Skip to main content
. 2022 Mar 9;12:845540. doi: 10.3389/fonc.2022.845540

Figure 1.

Figure 1

Cumulative incidence of infections post CD19-CAR T cell therapy in pediatric and AYA patients. The cumulative incidence (CI) of infection post CD19-CAR T cell therapy, as a function of the day of infection onset, is depicted for the entire study period (day 1 – 90). (A) The cumulative incidence of first infection, such that each patient may contribute only once (either bacterial, viral and/or fungal infection, whichever occurred first). Most patients (73.7%) experienced their first infection within the initial 28 days post CAR T cells, with a 36.7% CI (95% confidence interval: 21.6 - 52). The cumulative incidence of first (B) bacterial infection, with a 23.7% CI (95% confidence interval: 11.6 – 38.3), (C) viral infection, with a 18.2% CI (95% confidence interval: 7.9 – 31.8), and (D) fungal infection, with a 2.6% CI (95% confidence interval: 0.2 – 12), by day 28 post CAR T cell infusion.